Last reviewed · How we verify

NCT07131033

Esketamine Combined With Magnesium Sulfate for Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy

Active, enrolled Phase 1, PHASE2 Last updated 19 August 2025
What this trial tests

Phase 1, PHASE2 trial testing Esketamine in Laparoscopic Cholecystectomy in 120 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
6 May 2025
Primary endpoint
31 August 2025
30 September 2025

Quick facts

Lead sponsorThe Second People's Hospital of Huai'an
PhasePhase 1, PHASE2
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment120
Start date6 May 2025
Primary completion31 August 2025
Estimated completion30 September 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The Second People's Hospital of Huai'an

Who can join

Adults 18 to 65, any sex, with Laparoscopic Cholecystectomy or Alleviate Postoperative Fatigue Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Laparoscopic cholecystectomy (LC), while minimally invasive, triggers postoperative fatigue syndrome (POFS) through mechanisms including ischemia-reperfusion injury, neuroendocrine stress (sustained cortisol elevation), and inflammation-driven mitochondrial dysfunction (IDO-mediated kynurenine production). Esketamine, an NMDA receptor antagonist, counteracts POFS by blocking central sensitization, suppressing neuroinflammation (e.g., microglial IL-6 release), and enhancing neuroplasticity via BDNF/TrkB upregulation. Magnesium sulfate complements this by antagonizing NMDA/voltage-gated calcium channels to reduce inflammation and calcium overload, while optimizing cellular energy metabolism as an ATPase cofactor and alleviating muscle spasms. Crucially, their combination holds synergistic potential: esketamine targets central fatigue pathways, while magnesium addresses peripheral metabolic and muscular components. This study aims to determine their individual and interactive effects on POFS, recovery quality, and sleep outcomes in LC patients, establishing an efficient, safe strategy to accelerate postoperative rehabilitation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Esketamine

Trials testing the same drug.

Other recruiting trials for Laparoscopic Cholecystectomy

Currently open trials in the same condition.

Other The Second People's Hospital of Huai'an trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07131033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing